Literature DB >> 9625142

Acute hepatitis, autoimmune hemolytic anemia, and erythroblastocytopenia induced by ceftriaxone.

F Longo1, P Hastier, M J Buckley, R M Chichmanian, J P Delmont.   

Abstract

An 80-yr-old man developed acute hepatitis shortly after ingesting oral ceftriaxone. Although the transaminases gradually returned to baseline after withholding the beta lactam antibiotic, there was a gradual increase in serum bilirubin and a decrease in hemoglobin concentration caused by an autoimmune hemolytic anemia and erythroblastocytopenia. These responded to systemic steroids and immunoglobulins. Despite the widespread use of these agents this triad of side effects has not previously been reported in connection with beta lactam antibiotics.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9625142     DOI: 10.1111/j.1572-0241.1998.239_a.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  4 in total

1.  Identification and Characterization of Cefazolin-Induced Liver Injury.

Authors:  Saleh A Alqahtani; David E Kleiner; Marwan Ghabril; Jiezhun Gu; Jay H Hoofnagle; Don C Rockey
Journal:  Clin Gastroenterol Hepatol       Date:  2014-12-18       Impact factor: 11.382

2.  A case of ceftriaxone-induced liver injury and literature review.

Authors:  Matteo Guarino; Benedetta Perna; Alessandra Pastorelli; Paolo Bertolazzi; Giacomo Caio; Martina Maritati; Roberto De Giorgio; Carlo Contini
Journal:  Infez Med       Date:  2022-06-01

3.  Ceftriaxone-induced toxic hepatitis.

Authors:  Erdal Peker; Eren Cagan; Murat Dogan
Journal:  World J Gastroenterol       Date:  2009-06-07       Impact factor: 5.742

4.  Antibiotic-Induced Liver Injury in Paediatric Outpatients: A Case-Control Study in Primary Care Databases.

Authors:  Carmen Ferrajolo; Katia M C Verhamme; Gianluca Trifirò; Geert W 't Jong; Gino Picelli; Carlo Giaquinto; Giampiero Mazzaglia; Bruno H Stricker; Francesco Rossi; Annalisa Capuano; Miriam C J M Sturkenboom
Journal:  Drug Saf       Date:  2017-04       Impact factor: 5.606

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.